

**Financial Statements**

**Rightsmile, Inc.**

**For the Periods Ending December 31, 2012 and December 31, 2013**



**Rightsmile, Inc.**  
**Balance Sheet**  
**For the Twelve Months Ended 12/31/12 and 12/31/13, Respectively**  
**Unaudited**

Period Ending	December 31, 2013	December 31, 2012
<b>Assets</b>		
<b>Current Assets</b>		
Cash & Cash Equiv.	36,247	37,413
Accounts Rec.	226,659	16,573
Inventory	4,134	11,131
Contingent Assets	80,000	80,000
Deferred Tax Asset	1,376,944	1,278,583
<b>Total Current Assets</b>	<b>1,723,984</b>	<b>1,423,700</b>
 <b>Fixed Assets</b>		
Fixed Assets – Net	341,519	398,476
Intangible Assets	550,796	590,854
Investment in Subsidiaries	0	60,000
<b>Total Fixed Assets</b>	<b>892,315</b>	<b>1,049,330</b>
<b>Total Assets</b>	<b>2,616,299</b>	<b>2,473,030</b>
 <b>Liabilities</b>		
<b>Current Liabilities</b>		
Accounts Payable	0	0
Notes Payable	31,900	31,900
Accrued Interest	8,613	2,871
Unpaid Wages	40,685	24,942
Disputed Obligation Allowance	211,484	205,742
<b>Total Current Liabilities</b>	<b>292,682</b>	<b>265,455</b>
<b>Long Term Liabilities</b>	<b>0</b>	<b>0</b>
 <b>Shareholder's Equity</b>		
Common Stock, 30,000,000,000 Authorized, 29,999,999,468 Outstanding, Par Value \$.00001 as of 12/31/13	300,000	43,442
Preferred Stock, 5,000,000 Authorized, 3,565,000 Outstanding, Par Value \$.001 as of 12/31/13	3,565	3,865
Additional Paid In Capital	4,463,689	4,377,731
Common Shares Deliverable	-2,164	0
Treasury Stock	-1	-1
Accumulated Retained Earnings (Loss)	-2,283,292	-2,125,111
Net Income (Loss)	-158,180	-92,351
<b>Total Shareholder's Equity</b>	<b>2,323,617</b>	<b>2,207,574</b>
<b>Total Liabilities + Shareholder's Equity</b>	<b>2,616,299</b>	<b>2,473,029</b>
	0	0

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Rightsmile, Inc.**  
**Statement of Operations and Retained Earnings**  
**For the Twelve Months Ended 12/31/12 and 12/31/13, Respectively**  
**Unaudited**

Period Ending	December 31, 2013	December 31, 2012
Total Revenue	55,048	161,381
Cost of Revenue		
Lab Expenses	2,411	12,775
Freight & Delivery	1,543	19,662
Other Transportation	3,145	22,306
Total Costs of Goods Sold	7,099	54,743
Gross Profit	47,949	106,638
Operating Expenses		
Admin & General Exp.	45,417	120,534
Amortization	40,057	10,014
Depreciation	56,957	67,341
Sales & Marketing	2,438	470
Total Operating Expenses	144,869	198,359
Net Operating Profit (Loss)	-96,920	-91,721
Interest Expense	1,260	630
Net Income (Loss) Before Extraordinary Exp.	-98,180	-92,351
Liquidation of Subsidiary	60,000	0
Net Income (Loss) to Common	-158,180	-92,351
Beginning Retained Earnings	-2,125,111	-2,032,760
Ending Retained Earnings	-2,283,292	-2,125,111
Net Loss Per Common Share	\$(0.00007611)	

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Rightsmile, Inc.**  
**Statement of Cash Flows**  
**For the Twelve Months Ended 12/31/12 and 12/31/13, Respectively**  
***Unaudited***

<b>Period Ending</b>	<b>December 31, 2013</b>	<b>December 31, 2012</b>
Cash Flows from Operating Activities		
Net Income (Loss)	-98,180	-92,351
Adjustments to Reconcile to Net Cash		
Depreciation	56,957	67,341
Amortization	40,057	10,014
Net Cash from Operating Activities	-1,166	-14,996
Cash Flows from Investing Activities		
Disposition of Assets		
Net Cash from Investing Activities	0	0
Cash Flows from Financing Activities		
Proceeds from Loans		45,045
Net Cash from Financing Activities	0	45,045
<b>Gain (Loss) in Cash and Cash Equivalents</b>	<b>-1,166</b>	<b>30,049</b>
Cash and Cash Equivalents as of		
Beginning of the Period	37,413	7,364
Cash and Cash Equivalents as of		
End of the Period	36,247	37,413

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rightsmile, Inc.  
**Statement of Changes in Stockholders' Equity**  
For the Twelve Months Ended 12/31/12 and 12/31/13, Respectively  
*Unaudited*

	Common Stock		Preferred Stock		Additional Paid In Capital	Accumulated Deficit
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>		
<b>Balance at December 31, 2011</b>	2,411,657,296	\$24,116.57	865,000	\$865.00	\$2,079,469.00	-\$1,917,246.00
Net Income (Loss) – 2011						-\$115,514.00
<b>Balance at December 31, 2012</b>	4,344,206,740	\$43,442.07	3,865,000	\$3,865.00	\$4,377,731.00	-\$2,032,760.00
Net Income (Loss) – 2012						-\$92,351.47
<b>Balance at December 31, 2013</b>	29,999,999,468	\$299,999.99	3,565,000	\$3,565.00	\$4,463,689.00	-\$2,125,111.47
Net Income (Loss) – 2013						-\$158,180.06
					<b>Total 12/31/13</b>	<b>-\$2,283,291.53</b>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**RightSmile, Inc.**  
**Notes to Financial Statements for the Periods Ending 12/31/12 & 12/31/13**  
**As of December 31, 2013**

**Note 1. Organization, History and Business**

RightSmile, Inc., (“the Company”) was incorporated in Texas in February, 2001. The Company was re-domiciled in the State of Wyoming on September 20, 2013.

RightSmile, Inc. completed a reverse merger with BG Medical Technologies, Inc., on January 18, 2012. The Company intends to formally change its name from RightSmile, Inc., to BG Medical Technologies, Inc., and its ticker symbol with FINRA. RightSmile, Inc. is referred to herein as either the “Company” or, in discussing operations subsequent to January 18, 2012, “BG Medical”. RightSmile acquired BG Medical Technologies, Inc., replacing executive management, and transitioned its core business model to software and technology development specific to medical marijuana, and the complimentary and alternative medicine industry.

**Plan of Operation**

In February 2011, RightSmile acquired Kazore, Inc. dba Full Spectrum Media (now DevTek, LLC), changing its core business from teeth whitening systems to online marketing and development, including web, mobile application, and search engine optimization. In January 2012, RightSmile acquired BG Medical Technologies, Inc., replacing executive management, and began the transition of its core business model to software and technology development specific to medical marijuana, and the complimentary and alternative medicine industry. In 2013, the Company wound down DevTek, LLC, liquidating DevTek assets to cover outstanding debts and liabilities specific to DevTek, LLC. BG Medical maintains in-house labor to fulfill all previous DevTek related contributions, including contractual online marketing and development, including web, mobile application, and search engine optimization.

BG Medical develops Internet technology and biotechnology, focusing on medical cannabis, cannabis commerce, and natural health care solutions. Its products collect data through a network of proprietary software, utilized by patients, retail operators, and medical professionals. The Company's current flagship product, BudGenius.com, is a social web platform designed to assist cannabis patients in selecting regionally available medicine paired to their needs. The Company operates an analytical chemistry laboratory designed for natural medicine study, which is utilized to determine potency and safety guidance for patients and medicine manufacturers. Data collected from the laboratory is combined with patient feedback to produce information that benefits retail operators and informs patients on best available treatment options. BudGenius.com maintains the most comprehensive online public database for scientifically tested cannabis worldwide.

In 2010, BG Medical's BudGenius product entered the alternative healthcare market, becoming the nation's most popular medical cannabis testing laboratory. BudGenius' laboratory utilizes gas chromatography machines to conduct its testing procedures. This is similar to methods employed by pharmaceutical laboratories and biotech research firms. BudGenius results are displayed online upon BudGenius.com and within deployable website tools provided to clients. Results are also shown inside cannabis dispensaries throughout California. BudGenius utilizes custom software to pair specific plant genetics to patient ailments such as pain relief, anxiety, and nausea. Assuming financial resources are in place to do so, BudGenius plans to expand services to also address critical ailments such as cancer,

Parkinson's Disease, Alzheimer's, and more.

BudGenius' custom analysis software is the primary differentiator between itself and competitive testing laboratories. BudGenius combines analytical chemistry research with social web software that receives patient feedback (crowd sourcing) to determine the net medical effects of chemicals present within plant medicines. The BudGenius software engine reaches its conclusions by evaluating pre-programmed *quantitative* scientific trial data from (i) published studies in scientific journals and articles listing (ii) exact quantities consumed and (iii) researcher-observed effects; and then combining these calculations with *qualitative data* from (iv) crowd sourced patient feedback from website-submitted reviews, listing (v) relative quantity consumed and (vi) self-observed effects. The software engine "intelligence" is increased as additional data is added in real-time.

A variety of natural medicine treatment programs continue to gain popularity globally. Additionally, one third of the U.S. population resides in a region with favorable medical cannabis laws. However, in recognition of cannabis legal ambiguities, BG Medical's product strategy is strictly focused on data collection, data analysis, and data display. BG Medical does not sell, grow, harvest, cultivate, or distribute medical cannabis.

On occasion BG Medical also provides technical marketing services to third party clients, including design consultation, social Internet advisement, software engineering, and campaign management for web and mobile audiences.

BG Medical Technologies is focused on building medical treatment infrastructures that combine interactive desktop and mobile applications to provide an affordable alternative to rising healthcare cost concerns.

Management does not believe that cash from operations will be sufficient to meet its cash obligations, and it will be required to raise additional capital through private securities offerings to fund its research, development, and the planned expansion of its operations. In late 2013, BG Medical entered into an agreement with a reputable private equity firm to provide capital financing, although there can be no assurance that BG Medical will be able to raise the required capital to complete its goals in full.

## **Results of Operations**

BG Medical applies two primary technology strategies, each centered on Internet-based healthcare services, data collection, and data analysis. The first strategy focuses on technologies related specific to state-approved medical cannabis treatment programs, while the other focuses on technologies related to naturopathic healthcare and complimentary alternative medicine. BG Medical has formed its mission directives around the belief that marijuana as a medical application is an evolving world viewpoint that is introducing mainstream consumers to the intersection of advanced plant-based treatments with socially-driven Internet technology.

In Q4 2012, the Company completed debt obligations that had been negotiated in the previous quarter. Upon completion, BG Medical reevaluated the relationship the company previously held with Baron Capital Enterprises (BCAP), a debt holder in the Company, and consultant to debt holders associated with the Company prior to the January 2012 reverse merger with BG Medical. Executive management concluded that financing commitments previously set forth by BCAP to BG Medical had not met expectations. As a result of an internal study examining historical transactions, management further alleged that ongoing actions by BCAP could cause irreparable harm to both Company and

shareholders. To protect shareholder interests and future business interests, the Company sought to limit uncontrolled free trading shares from entering the marketplace from methodologies that did not support business growth and/or shareholder earnings. Stopgap measures were put into place that limited corporate communications until a long-term strategy with sufficient resources had been established. The resultant lack of capital financing as previously planned, coupled with the presence of an unresolved capital financing relationship, created challenges for BG Medical in adhering to stated growth projections that were dependent upon capital support. Furthermore, medical cannabis policy changes in San Diego, CA and Long Beach, CA forced closure of key BudGenius.com clients and prospective clients. These unexpected closures reduced Company profits due to significant resources that had been invested into expanding client relationships within these regions. Evolving municipal policy changes represent operational risks inherent to the medical cannabis industry, and when viewed as a whole, illustrate the consistent ebb and flow for this emerging market.

Throughout 2013, the Company placed its focus on resolving market volatility allegedly resultant from a former financing relationship with Baron Capital Enterprises (BCAP) and its principals, an entity and individual(s) closely involved in providing past financing to the public entity prior to the 2012 reverse merger, and to a lesser degree, minor financing during the Q1 2012 and Q2 2012 post reverse merger period. BG Medical has no plans to enter into further debt arrangements with previous promissory note holders. The company wishes to distance itself from BCAP and remains committed to preserving shareholder value. Due to the disruptive nature of unwinding the aforementioned relationship(s), the undertaking of preserving the Company's future as an attractive investment prospect eclipsed daily operations and affected previously scheduled technology development. With limited capital resources available, guarding the long-term growth potential of the Company led to a reduction in near-term revenues. These actions forced the introduction of leaner operation models that serve today as a valuable and efficient blueprint for the company as it enters 2014, its fourth year in operation.

In Q2 2013, the Company closely aligned itself and contributed significant labor resources to passing newly proposed Los Angeles city legislation, which if passed, would have introduced mandatory medical marijuana laboratory testing practices for all cannabis dispensaries (retail outlets) within city borders. The Company supported the proposition for the changes it would have introduced to the limited regulatory environment of Los Angeles. In addition to mandating analytical testing for all cannabis products, the proposition also included operational guidance for dispensaries, consumer protections, and neighboring resident protections. Unfortunately, an opposing bill was passed that did not impose testing regulations and further reduced the number of dispensaries allowed to conduct business within Los Angeles. This affected BudGenius market growth in the Los Angeles region was subsequently affected by the closure of several clients as per the passed proposition. However, the subsequent limited enforcement of certain measures within the bill has created an ongoing topic of public debate in regards to its effectiveness. BG Medical expects future legislation to address these issues, including the addition mandates for testing. In relation to ongoing trends, mandatory testing throughout all states and municipalities is expected as the cannabis industry continues to mature. BG Medical and BudGenius currently serves several Los Angeles businesses, that despite the lack of current legislative decree, willfully choose to conduct laboratory testing for the benefit of their patients. BG Medical continues to support and contribute to legislation throughout the nation that proposes cannabis testing as a necessary component for patient safety and consumer knowledge.

As of Q4 2013, BG Medical successfully entered into capital agreements with a reputable finance firm to accelerate its proprietary technology development and to strengthen a market evaluation based on the Company's future earning potential. BG Medical continues to seek accredited investors and respectable financial relationships to fulfill Company capital needs and growth development through its planned

expansion. The successful implementation and launch of recreational marijuana legislation in Colorado has led to significantly enhanced interest from mature investment firms seeking to capitalize on industry growth opportunities. As a seasoned company within the marijuana industry, BG Medical is well positioned to engage these opportunities.

BG Medical's medical cannabis platform, BudGenius.com, operates in both the largest state-approved population for medical cannabis dispensaries nationwide and the most densely populated local region, California and the Los Angeles metropolitan area, respectively. BudGenius has developed the most highly visited web portal for a cannabis laboratory. Up to 12,000 patients per day research their medicine on BudGenius.com. BudGenius has also created what BG Medical believes to be the largest online database of high-definition microscopic photographs of cannabis strains in the world.

BG Medical expects ongoing and accelerating growth in state-approved medical cannabis patient communities nationwide. However, sales revenue in the cannabis market segment is dependent on market trends. Volatility in mature medical cannabis markets such as California, Colorado, and Washington are expected through the ongoing clarification of state and federal positions regarding medical cannabis distribution. Cautious growth rates are expected in emerging markets in Arizona, Illinois, Michigan, Nevada, Oregon, and Washington DC, as well as latent markets in Alaska, Connecticut, Delaware, Hawaii, Maine, Maryland, Massachusetts, Montana, Nevada, New Hampshire, New Jersey, New Mexico, Rhode Island, and Vermont. BG Medical believes new market growth rates will increase significantly as mature markets set non-volatile standards for emergent markets to emulate. Further market changes are expected as a result of the 2016 United States elections. The Company expects recreational legalization to occur within California, and expects to be politically active in these agendas as it has been with previous legislative efforts. Marijuana industry growth is likely to be further propelled by the results of pending favorable cannabis legislation introduced in Florida, Kansas, Minnesota, Missouri, New York, Ohio, Pennsylvania, and South Carolina, and future state legislative efforts. Consolidation in the quantity of regional cannabis dispensaries is occurring in mature markets, leading to an expected decrease in revenue potential for products and services based on dispensary density (such as advertising and location portals), in addition to an expected increase in revenue potential for products and services based on recurring patient services, education, and medicine safety (such as the BudGenius product platform). BG Medical expects these trends to continue in a similar manner to many market lifecycles in which newly implemented technologies lower long-term operational costs, and create a price-competitive marketplace that becomes reliant on the efficiency of underlying technology platforms.

Upon facilitation of capital financing agreements erected in Q4 2013, new products and services for consumers and businesses are expected to resume development for enhancing the BudGenius software and data collection platform, including but not limited to, mobile app development, online transparency for laboratory workflow, marijuana genetics and strain mapping, marijuana heritage profiles to highlight sustained and exceptional farmer pedigree, business intelligence data gathering tools, consumer purchase pattern analysis, medical efficacy analysis, loyalty programs, portable diagnostic hardware for patients, and internal tools to optimize company workflow for the purpose of reducing cost of goods sold. A modified release schedule has not yet been determined.

## **Note 2. Summary of Significant Accounting Policies**

### **Revenue Recognition**

Revenue is derived from sales of products to distributors and consumers. Revenue is recognized in

accordance with Staff Accounting Bulletin (“SAB”) No. 101, “Revenue Recognition in Financial Statements,” as revised by SAB No. 104. As such, the Company recognizes revenue when persuasive evidence of an arrangement exists, title transfer has occurred, the price is fixed or readily determinable, and collectability is probable. Sales are recorded net of sales discounts and terms are recorded by contract.

Accounts receivable is reported at the customers’ outstanding balances, less any allowance for doubtful accounts. Interest is not accrued on overdue accounts receivable.

### **Allowance for Doubtful Accounts**

An allowance for doubtful accounts on accounts receivable is charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and information collected from individual customers. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.

### **Stock Based Compensation**

When applicable, the Company will account for stock-based payments to employees in accordance with ASC 718, “Stock Compensation” (“ASC 718”). Stock-based payments to employees include grants of stock, grants of stock options and issuance of warrants that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

The Company accounts for stock-based payments to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Stock-based payments to non-employees include grants of stock, grants of stock options and issuances of warrants that are recognized in the consolidated statement of operations based on the value of the vested portion of the award over the requisite service period as measured at its then-current fair value as of each financial reporting date.

The Company calculates the fair value of option grants and warrant issuances utilizing the Binomial pricing model. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. ASC 718 requires forfeitures to be estimated at the time stock options are granted and warrants are issued to employees and non-employees, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant. The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period. In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee termination patterns. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period.

During the period January 1, 2012 through December 31, 2013, the Company did not recognized any stock-based compensation. No options have been granted to date.

### **Loss per Share**

The Company reports earnings (loss) per share in accordance with ASC Topic 260-10, "Earnings per Share." Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since there are no dilutive securities.

### **Cash and Cash Equivalents**

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

### **Concentration of Credit Risk**

The Company primarily transacts its business with one financial institution. The amount on deposit in that one institution may from time to time exceed the federally-insured limit.

### **Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### **Business segments**

ASC 280, "*Segment Reporting*" requires use of the "*management approach*" model for segment reporting. The management approach model is based on the way a company's management organizes segments within [the company](#) for making operating decisions and assessing performance. [The Company](#) determined it has one operating segment as of December 31, 2013

### **Income Taxes**

The Company accounts for its income taxes under the provisions of ASC Topic 740, "Income Taxes." The method of accounting for income taxes under ASC 740 is an asset and liability method. The asset and liability method requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

### **Recent Accounting Pronouncements**

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financials properly reflect the change. The Company currently does not have any recent



through December 31, 2013, there were no income tax, or related interest and penalty items in the income statement, or liabilities on the balance sheet. The Company files income tax returns in the U.S. federal jurisdiction and Wyoming state jurisdiction. We are not currently involved in any income tax examinations.

#### **Note 4. Related Party Transactions**

None.

Related Party Stock Issuances:

On or about November 25, 2013, the company issued 24,665,700,000 restricted shares of common stock, par value \$.00001, to Salvatore Tuzzolino as consideration for past and future services rendered to the company and cash receivables;

On or about November 25, 2013, the company issued Salvatore Tuzzolino, 2,000,000 restricted shares of common stock, par value \$.00001, pursuant to Mr. Tuzzolino's conversion of 2,000 shares of the company's Series A Preferred stock, at a conversion rate of 10,000 for 1; and

On or about December 6, 2013, the company issued 1,990,092,728 restricted shares of common stock, par value \$.00001, to Salvatore Tuzzolino as consideration for the forgiveness of certain amounts owed to Mr. Tuzzolino by the company and cash receivables;

Mr. Tuzzolino is a ten (10%) percent shareholder of the Issuer.

#### **Note 5. Stockholders' Equity**

##### **Common Stock**

The holders of the Company's common stock are entitled to one vote per share of common stock held.

As of December 31, 2013 the Company had 29,999,999,468 shares issued and outstanding.

#### **Note 6. Commitments and Contingencies**

##### ***Commitments:***

The Company currently has no long term commitments as of our balance sheet date.

##### ***Contingencies:***

In 2009 through 2011 the Company entered into a series of promissory notes with Baron Capital Enterprise, Inc. The Company disputes the validity of the alleged obligations and claims damages against Baron Capital Enterprise, Inc. for, among other matters, material breach of contract. The Company's balance sheet reflects both the Company's contingent claim as well as an allowance for the disputed obligation.

**Note 7 – Net Income(Loss) Per Share**

For the period ending December 31, 2013, the shareholders of the Company has registered a cumulative net loss per common share of \$.00008

**Note 8. Notes Payable**

The Company has a series of promissory notes in the aggregate principal amount of \$31,900 bearing interest at a rate of eighteen (18%) percent currently outstanding.

**Note 9. Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Currently, the Company has limited operating history and has incurred operating losses, and as of December 31, 2013 the Company had an accumulated deficit of \$2,283,291.53 These factors raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company's capital requirements will depend on many factors including the success of the Company's development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There is no assurance that such financing will be available in the future. The conditions described above raise substantial doubt about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

**Note 11. Subsequent Events**

None.

## **Issuer Certification**

I, Aaron Stanz hereby certify that:

1. I have reviewed these Financial Statements for the years ending December 31, 2012 and December 31, 2013, respectively;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 15, 2015

/s/ Aaron Stanz

---

Chief Executive Officer